• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Emerg Microbes Infect . Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses from humans in the United Stat

tetano

Editor, Senior Moderator
Emerg Microbes Infect


. 2025 Dec 15:2601372.
doi: 10.1080/22221751.2025.2601372. Online ahead of print. Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses from humans in the United States, October 2024 to February 2025

Philippe Noriel Q Pascua[SUP] 1 [/SUP], Anton P Chesnokov[SUP] 1 [/SUP], Ha T Nguyen[SUP] 1 [/SUP], Chloe Champion[SUP] 1 [/SUP], Rongyuan Gao[SUP] 1 [/SUP], Juan A De La Cruz[SUP] 1 [/SUP], Yunho Jang[SUP] 1 [/SUP], Yasuko Hatta[SUP] 1 [/SUP], Zhu Guo[SUP] 1 [/SUP], Timothy M Uyeki[SUP] 1 [/SUP], Han Di[SUP] 1 [/SUP], James Stevens[SUP] 1 [/SUP], Charles T Davis[SUP] 1 [/SUP], Larisa V Gubareva[SUP] 1 [/SUP]



Affiliations
Free article Abstract

Since October 2024, 55 human cases of influenza A(H5N1), clade 2.3.4.4b, were reported in the US. Sequencing of 46 viruses identified genotypes B3.13, D1.1, and D1.3. Genomes of viruses were analyzed for mutations associated with reduced antiviral susceptibility. Except for two, viruses from human cases were assessed as susceptible to antivirals and confirmed by in vitro susceptibility testing of representative viruses with M2 blockers, neuraminidase (NA) inhibitors, and the polymerase acidic (PA) inhibitor baloxavir. One D1.1 virus had an M2-S31N substitution, which conferred cross-resistance to M2 blockers. One B3.13 virus had a PA-I38M substitution and displayed 17-fold reduced baloxavir susceptibility in cell culture. In mice, baloxavir, given orally at 5, 15, and 45 mg/kg bid for 5 days starting at 2 hours post-infection, was notably less effective against the PA-I38M virus compared to the closely matched control virus, as shown by survival rate, time-to-death, weight loss, and viral replication in various organs. Replication of the PA-I38M virus was mildly attenuated in mice but not in cell culture. Viruses collected from animals also contained mutations associated with reduced antiviral susceptibility, including M2-S31N, PA-I38 T/M, and NA-H275Y, albeit at low frequency. Regardless of genotype, most mutations were found in NA. Using recombinant NA proteins generated from B3.13 and D1.1 backgrounds, we showed that among mutations that reduced susceptibility of NA inhibitors, only NA-H275Y had no effect on the enzyme's function. Spontaneous emergence of drug-resistant influenza viruses, especially those that maintain replicative fitness, pose persistent threat to human health and must be closely monitored.

Keywords: A(H5N1) viruses; baloxavir; bovine flu; drug resistance; neuraminidase; neuraminidase inhibitors.

 
Back
Top Bottom